Amneal Pharmaceuticals (AMRX) Stock Statistics & Valuation Metrics

Amneal Pharmaceuticals has a market cap or net worth of $4.17B. The enterprise value is $6.59B.

Amneal Pharmaceuticals has 314,629,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Amneal Pharmaceuticals’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is 13.80%.

The current PE Ratio of Amneal Pharmaceuticals is 54.8. Amneal Pharmaceuticals’s PEG ratio is -0.34.

In the last 12 months, Amneal Pharmaceuticals had revenue of 3.02B and earned 72.06M in profits. Earnings per share was 0.23.

In the last 12 months, operating cash flow was 339.99M and capital expenditures -103.04M, giving a free cash flow of 236.95M billion.

Amneal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Amneal Pharmaceuticals upcoming earnings date is May 1, 2026, Before Open (Confirmed).

Amneal Pharmaceuticals as a current ratio of 2.17, with Debt / Equity ratio of -3865.40%

In the past 12 months, Amneal Pharmaceuticals has paid 11.28M in taxes.

Amneal Pharmaceuticals EV to EBITDA ratio is 10.56, with an EV/FCF ratio of 23.61.

Amneal Pharmaceuticals has $310.87M in cash and marketable securities with $2.74B in debt, giving a net cash position of -$2.43B billion.

Gross margin is 36.88%, with operating margin of 14.02%, and net profit margin of 2.39%.

The average price target for Amneal Pharmaceuticals is $16.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy